as 10-30-2025 9:34am EST
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.1B | IPO Year: | 2004 |
| Target Price: | $35.60 | AVG Volume (30 days): | 767.7K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.53 | EPS Growth: | -74.00 |
| 52 Week Low/High: | $16.52 - $22.00 | Next Earning Date: | 11-06-2025 |
| Revenue: | $370,229,000 | Revenue Growth: | 12.02% |
| Revenue Growth (this year): | 7.98% | Revenue Growth (next year): | 11.60% |
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Zacks
20 days ago
Simply Wall St.
a month ago
MT Newswires
5 months ago
Business Wire
5 months ago
Argus Research
5 months ago
MT Newswires
5 months ago
Business Wire
5 months ago
Business Wire
5 months ago
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.